Futurity · Health

Malaria parasite vulnerability discovered, offering new vaccine hope

Researchers identified a weakness in the Plasmodium vivax (P. vivax) malaria parasite, potentially leading to a new vaccine. This parasite affects millions globally, especially in Central/South America and Southeast Asia.

The discovery targets a site antibodies can block, preventing P. vivax from invading liver cells. This is key as P. vivax forms dormant stages causing relapses months or years later. Targeting this site could prevent disease and transmission, as relapse infections are a major source of P. vivax spread.

Scientists found a new epitope on the parasite's surface protein (CSP) that antibodies can target. This offers a novel vaccine target for P. vivax, a parasite receiving less research than P. falciparum despite its widespread impact.

Two independent teams found the same vulnerable region, one studying parasite/immune responses, the other molecular targets. This convergence of evidence from different approaches validated the discovery.

While significant, eradicating malaria remains a long-term goal. P. vivax's dormant liver stage is a major control challenge, unlike P. falciparum's acute illness.

A vaccine is years away, but the path is clearer. Next steps involve creating effective vaccine formulations for human trials.

AI-samenvatting op basis van de bron.